BRAHMS copeptin assay to rule out myocardial infarction in patients with acute chest pain (MTG4)
NICE has developed medical technology guidance on the BRAHMS copeptin assay.
NICE medical technology guidance addresses specific technologies notified to NICE by manufacturers. The 'case for adoption' recommendations are based on the claimed advantages of introducing the specific technology compared with current management of the condition. This 'case' is reviewed against the evidence submitted and expert advice. The medical technology guidance on the BRAHMS copeptin assay recommends further research. This recommendation is not intended to preclude the use of the technology in the NHS but to identify further evidence which, after evaluation, could support a recommendation for wider adoption.
NICE has said that at the moment the BRAHMS copeptin assay is promising, but that there is not enough evidence on how it would affect NHS services for it to be used routinely. NICE has recommended that more research on the BRAHMS copeptin assay is done.
- MTG4 BRAHMS copeptin assay to rule out myocardial infarction in patients with acute chest pain : guidance (web format)
This page was last updated: 08 May 2012
Information for the public
Implementation tools and resources
- None available
See this guidance in practice
The summary of the key recommendations in the guidance written for patients, carers and those with little medical knowledge and may be used in local patient information leaflets.
Quick Reference Guide
The quick reference guide presents recommendations for health professionals
The published NICE clinical guidance, contains the recommendations for health professionals and NHS bodies.
The published full clinical guidance for specialists with background, evidence, recommendations and methods used.